Efficacy Of Neoadjuvant Chemotherapy In The Treatment Of Low Rectal Carconoma

Objective: Preliminarily evaluate the efficacy of neoadjuvant chemotherapyin the treatment of low rectal cancer.Method: Low rectal cancer patients were selected from among the casesseen at the Affiliated Tumor Hospital of Guangxi Medical University fromAugust2009to August2013. The82patients each had a margin of3–6cm intumor distance from the anus. According to the treatment method, the cases weredivided into group A (31cases, preoperative neoadjuvant chemotherapy+surgery group) and group B (51cases, direct surgery without neoadjuvanttherapy). The two groups were observed and clinical data on surgical approach,postoperative complications, and postoperative follow-up (including anusfunction and the local recurrence rate) were recorded.Results: The tumor resection rates in the two groups were100%, and allunderwent R0resection. The sphincter-saving rates in group A and B were71%and47%respectively. The groups had no perioperative deaths, andpostoperative complications were13%for A and10%for B. In the follow-upperiod, each patient experienced recovered functioning in the anus sphincter, andlocal recurrence rates were3.2%and9.8%respectively. Each group had one death, the causes of which were systemic metastasis of multiple organ failure.The preservation rate of the anal sphincter was higher in group A than in groupB (p <0.05). Postoperative complications, functional recovery of the anus, andthe local recurrence rate differences had no statistically significance (p>0.05).Conclusion: Neoadjuvant chemotherapy for low rectal cancer does notincreases the postoperative complications. The treatment also does not reducethe effect of tumor cure. This therapy can also significantly improve thepreservation rate of the anus sphincter in low rectal cancer and is worthy ofwidely clinical use.